CLDX
NASDAQCelldex Therapeutics Inc.
SectorHealth CareIndustryBiotechnology: In Vitro & In Vivo Diagnostic Substances
Price$32.96-0.12 (-0.35%)
01:30 PM07:45 PM
News · 26 weeks30-40%
2025-12-282026-06-21
Mix1990d
- Other8(42%)
- SEC Filings6(32%)
- Offering4(21%)
- Analyst1(5%)
Latest news
25 items- PRCelldex Presents Long-Term Barzolvolimab Results Demonstrating Sustained Off-Treatment Improvement in Angioedema in Patients with CSU at the European Academy of Allergy and Clinical Immunology Annual MeetingTreatment with barzolvolimab resulted in rapid, significant, and durable improvements in angioedema in patients with moderate to severe CSUSeven months after the completion of dosing (Week 76), up to 64% of patients treated with barzolvolimab who had angioedema at baseline remained angioedema-free Barzolvolimab has potential to shift treatment goals from symptom control to disease modificationResults continue to support ongoing Phase 3 trials of barzolvolimab in CSU; topline data expected in Q4 2026 HAMPTON, N.J., June 14, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today the presentation of long-term results from the Phase 2 study of barzolvolimab in a flash talk session at
- PRCelldex Presents Positive First-in-Human Results from Phase 1 Study of Novel Bispecific CDX-622 at the European Academy of Allergy and Clinical Immunology Annual MeetingCDX-622 is a novel, bispecific antibody combining mast cell depletion and TSLP inhibition, two independent pathways contributing to multiple I&I diseasesCDX-622 targets the soluble form of stem cell factor (SCF), depleting mast cells without measurably impacting other KIT functionsRapid, profound, dose-dependent, and durable reductions in serum tryptase observedWell-tolerated at all dose levels First company to demonstrate that neutralizing soluble SCF can selectively inhibit KIT signaling in mast cells HAMPTON, N.J., June 14, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) today presented positive results from the Phase 1 healthy participant study of CDX-622, a novel, bispecific antibody
- PRCelldex Announces Multiple Upcoming Presentations from Leading Mast Cell Targeting Pipeline at the Upcoming 2026 European Academy of Allergy and Clinical Immunology Annual Congress-- Flash talks on barzolvolimab clinical program in CSU and Cold Urticaria ---- Late-breaking poster presentation on CDX-622 -- HAMPTON, N.J., June 10, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today that three presentations from the barzolvolimab and CDX-622 programs will be shared at the upcoming European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress being held in Istanbul, Türkiye, on June 12-15, 2026. Results supporting Celldex's leadership and barzolvolimab's first-in-class, best-in-disease profile in chronic spontaneous urticaria (CSU) and cold urticaria (ColdU) will be presented in two flash talks. New, first-in-human results from the Phase 1 t
- SECSEC Form SCHEDULE 13G filed by Celldex Therapeutics Inc.SCHEDULE 13G - Celldex Therapeutics, Inc. (0000744218) (Subject)
- SECSEC Form 10-Q filed by Celldex Therapeutics Inc.10-Q - Celldex Therapeutics, Inc. (0000744218) (Filer)
- SECCelldex Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Celldex Therapeutics, Inc. (0000744218) (Filer)
- PRCelldex Reports First Quarter Financial Results and Provides Corporate UpdateEnrollment completed six months ahead of guidance in both barzolvolimab Phase 3 chronic spontaneous urticaria studies (EMBARQ-CSU 1 and 2); Topline data expected in Q4 26; BLA submission planned for 2027Phase 3 barzolvolimab cold urticaria and symptomatic dermographism study (EMBARQ-ColdU and -SD) actively enrolling Phase 1 CDX-622 proof of mechanism study in asthma ongoing2026 expected to deliver multiple key data readouts across the pipelineRaised $345 million in gross proceeds from a follow-on public offering, closed in April 2026 HAMPTON, N.J., May 07, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) today reported financial results for the first quarter ended March 31, 2026 and prov
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Celldex Therapeutics Inc.SCHEDULE 13G/A - Celldex Therapeutics, Inc. (0000744218) (Subject)
- SECSEC Form DEF 14A filed by Celldex Therapeutics Inc.DEF 14A - Celldex Therapeutics, Inc. (0000744218) (Filer)
- ANALYSTCelldex Therapeutics upgraded by Barclays with a new price targetBarclays upgraded Celldex Therapeutics from Underweight to Overweight and set a new price target of $45.00
- PRCelldex to Present at Upcoming Investor ConferenceHAMPTON, N.J., April 13, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today that management will participate in a fireside chat at H.C. Wainwright's 4th Annual Inflammatory Skin Disease Virtual Conference on Tuesday, April 14 at 3:30 pm ET. The webcast of the presentations will be available on the "Events & Presentations" page of the "Investors" section of the Celldex website. Replays will be available for 90 days following the event. About CelldexCelldex is pioneering new horizons in immunology to deliver life-changing therapies. We are relentless in our pursuit of novel antibody-based treatments that engage the human immune system and directly affect critical pathways to im
- PRCelldex Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional SharesHAMPTON, N.J., April 06, 2026 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. ("Celldex" or the "Company") (NASDAQ:CLDX) today announced the closing of its previously announced underwritten public offering of 11,896,750 shares of its common stock, which includes the exercise in full by the underwriters of their option to purchase an additional 1,551,750 shares of common stock at a public offering price of $29.00 per share. All of the shares sold in the offering were sold by Celldex. The gross proceeds to Celldex from this offering were approximately $345 million, excluding underwriting discounts and commissions and other offering-related expenses. Leerink Partners, TD Cowen, Guggenheim Sec
- SECSEC Form 424B5 filed by Celldex Therapeutics Inc.424B5 - Celldex Therapeutics, Inc. (0000744218) (Filer)
- SECCelldex Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits8-K - Celldex Therapeutics, Inc. (0000744218) (Filer)
- PRCelldex Announces Pricing of $300 Million Public Offering of Common StockHAMPTON, N.J., April 01, 2026 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. ("Celldex" or the "Company") (NASDAQ:CLDX) today announced the pricing of an underwritten public offering of 10,345,000 shares of its common stock at a public offering price of $29.00 per share. All of the shares to be sold in the offering are to be sold by Celldex. In connection with the offering, Celldex has also granted the underwriters a 30-day option to purchase up to an additional 1,551,750 shares of common stock at the public offering price, less the underwriting discounts and commissions. The Company expects to receive gross proceeds from the offering, excluding the exercise of the underwriters' option, if
- SECSEC Form 424B5 filed by Celldex Therapeutics Inc.424B5 - Celldex Therapeutics, Inc. (0000744218) (Filer)
- PRCelldex Announces Proposed Public Offering of Common StockHAMPTON, N.J., April 01, 2026 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. ("Celldex" or the "Company") (NASDAQ:CLDX) today announced that it has commenced an underwritten public offering for the sale of shares of its common stock. In addition, Celldex expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock offered in the offering. All of the shares of common stock are being offered by the Company. The final terms of the offering will depend on market and other conditions at the time of pricing, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offerin
- PRCelldex Presents Positive Data from Phase 2 Chronic Spontaneous Urticaria and Phase 2 Cold Urticaria and Symptomatic Dermographism Studies Demonstrating Rapid, Profound and Durable Improvements in Patient Quality of Life at AAD 2026- Improvements seen across all six DLQI Domains indicating broad, beneficial impact on quality of life -- Data further demonstrates first-in-class and best-in-disease barzolvolimab profile - HAMPTON, N.J., March 27, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) presented additional positive data from the completed Phase 2 clinical trials of barzolvolimab in chronic spontaneous urticaria (CSU) and cold urticaria (ColdU) and symptomatic dermographism (SD) demonstrating profound improvements in patient quality of life (QoL) across all measured domains: symptoms and feelings, daily activities, leisure, work and school, personal relationships and treatment. Barzolvolimab is a humanized mono
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Celldex Therapeutics Inc.SCHEDULE 13G/A - Celldex Therapeutics, Inc. (0000744218) (Subject)
- ANALYSTCelldex Therapeutics upgraded by Wolfe Research with a new price targetWolfe Research upgraded Celldex Therapeutics from Peer Perform to Outperform and set a new price target of $44.00
- PRCelldex Presents Positive Data Demonstrating Barzolvolimab Retreatment Achieves Similar Profound Efficacy to First Exposure in Patients with Cold Urticaria (ColdU) and Symptomatic Dermographism (SD) Further Demonstrating First-in-Class and Best-in-Disease Barzolvolimab Profile at AAAAI 2026- Late breaking Poster Presentation at AAAAI -- Ability to retreat facilitates a real-world paradigm in which treatment for ColdU and SD may be intermittent with barzolvolimab - HAMPTON, N.J., March 01, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) presented new positive data from the Phase 2 ColdU and SD Open Label Extension (OLE), highlighting that retreatment with barzolvolimab leads to rapid improvement in urticaria control after symptom recurrence. Barzolvolimab is a humanized monoclonal antibody with a completely novel mechanism of action that uniquely targets the root cause of ColdU and SD—the mast cell. The data were shared today in a late breaking poster presentation at the 2026
- PRCelldex Presents Additional Positive Data from Phase 2 Chronic Spontaneous Urticaria (CSU) and Phase 2 Cold Urticaria (ColdU) and Symptomatic Dermographism (SD) Studies Further Demonstrating First-in-Class and Best-in-Disease Barzolvolimab Profile at AAAAI 2026- Sustained off-treatment efficacy despite barzolvolimab clearance and normalization of tryptase, suggesting disease modification in patients with CSU treated for full 52 weeks -- Greatly improved quality of life and reduced disease impact for patients with ColdU/SD at Week 20 -HAMPTON, N.J., Feb. 27, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) presented additional positive data from the completed Phase 2 clinical trials of barzolvolimab in chronic spontaneous urticaria (CSU) and cold urticaria (ColdU) and symptomatic dermographism (SD). Barzolvolimab is a humanized monoclonal antibody with a completely novel mechanism of action that uniquely targets the root cause of CSU, ColdU and SD—
- PRCelldex Reports Fourth Quarter and Year End 2025 Financial Results and Provides Corporate UpdateEnrollment completed in both Phase 3 chronic spontaneous urticaria global registration studies (EMBARQ-CSU 1 and 2) six months ahead of guidance; Topline data expected in Q4 26; BLA submission planned for 2027Phase 3 cold urticaria and symptomatic dermographism study (EMBARQ-ColdU and -SD) actively accruing Enrollment completed in Phase 2 prurigo nodularis and atopic dermatitis studies with topline data expected in 2026 Phase 1 CDX-622 Proof of Mechanism study in asthma initiatedCompany prepares for landmark year of clinical readouts in 2026 HAMPTON, N.J., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) today reported financial results for the fourth quarter and year ended Decembe
- SECSEC Form 10-K filed by Celldex Therapeutics Inc.10-K - Celldex Therapeutics, Inc. (0000744218) (Filer)
- SECCelldex Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Celldex Therapeutics, Inc. (0000744218) (Filer)
CLDX FAQ
6 questionsWhat does Celldex Therapeutics Inc. do?
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-0159, a Phase I monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity; CDX-1140, a human agonist monoclonal antibody targeted to CD40, a key activator of immune response, which is found on dendritic cells, macrophages...Where does CLDX stock trade?
Celldex Therapeutics Inc. (CLDX) is listed on NASDAQ.What sector and industry is CLDX in?
Celldex Therapeutics Inc. operates in the Health Care sector, Biotechnology: In Vitro & In Vivo Diagnostic Substances industry.What are analysts saying about CLDX?
Celldex Therapeutics Inc. has had 8 recent analyst actions on file. The most recent action was from Barclays: Overweight with a $4500.00 price target on 2026-04-20. Recent price targets range from $2500.00 to $4800.00.What companies are similar to CLDX?
Notable peers in the same industry include SRNE (Sorrento Therapeutics Inc.), OTLK (Outlook Therapeutics Inc.), ALRN (Aileron Therapeutics Inc.), ONTX (Onconova Therapeutics Inc.), VTGN (Vistagen Therapeutics Inc.). Compare CLDX side-by-side with any of them on Quantisnow.How can I track CLDX on Quantisnow?
Quantisnow aggregates Celldex Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow CLDX to receive live email and push alerts on every new disclosure.